Sunshine Biopharma (SBFM)
Nasdaq Market Closed
Sunshine Biopharma Inc. is a pharmaceutical and life sciences company focused on commercial drug products and early-stage proprietary research. The company operates through subsidiaries that market generic prescription medicines in Canada, giving it exposure to established pharmaceutical distribution channels while it continues to pursue higher-risk development programs.
Its commercial activities include generic drugs used across a range of therapeutic categories, as well as over-the-counter health and nutrition products. This combination gives Sunshine Biopharma a broader operating base than a pure research-stage biotechnology company, although its public market profile is closely tied to the progress and prospects of its pipeline.
The company’s proprietary research is concentrated in areas with significant medical need, including oncology and antiviral therapy. Its development programs include K1.1, an mRNA-based candidate aimed at liver cancer, and SBFM-PL4, a protease inhibitor designed to target the PLpro enzyme associated with SARS coronavirus infections. These programs remain part of the company’s longer-term strategy to build value through novel drug development.
As a small-cap pharmaceutical business, Sunshine Biopharma is exposed to the opportunities and risks typical of the sector: regulatory review, clinical validation, financing requirements, manufacturing execution, and commercial competition. Its distinctive feature is the mix of marketed generic and consumer health products alongside proprietary drug candidates in cancer and infectious disease.
Last updated
- Market Cap
- 4.3M
- P/E
- —
- P/FCF
- —
- P/S
- 0.12
- Enterprise Value
- -2.61M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301
Why the Risk With Penny Stocks is Worth the Reward
How to Know When to Buy and Sell Penny Stocks, 3 Tips
Sunshine Biopharma Moves Principal Office to New York City
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
How to Use Social Media to Make Money Trading Penny Stocks
PPI Report Live: Producer Price Inflation Report Is Out, Here’s What It Shows
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
Sunshine Biopharma Announces Share Repurchase Program
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
10 Top Penny Stocks To Buy In June According To These Insiders Part 1
Hot Penny Stocks to Buy Now? 3 to Watch on May 5th, 2022
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
Best Penny Stocks to Buy as April Ends? 3 to Watch Today
Here's one way to potentially get more from a 60/40 portfolio
Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up
Trading Penny Stocks, April 5th, SBFM and TWTR Explode
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 4.3M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -2.61M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.2
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.12
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.69
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- -0.07
- EPS
- -3.74
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -5.86M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -28.07%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -21.62%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.22
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.98
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.18
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 28M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.66
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 8.09M | 8.58M | 9.42M | 9.41M | 8.9M |
| Gross profit | 2.18M | 3.03M | 3.07M | 3.42M | 2.73M |
| Operating income | -1.4M | -1.79M | -1.09M | -2.05M | -1.3M |
| EBITDA | -1.23M | -1.46M | -242.79K | -855.32K | -1.2M |
| Net income | -1.24M | -2.14M | -883.82K | -1.77M | -1.18M |
| Basic EPS | -2.5 | -4.6 | -1.9 | -3.9 | -4.4 |
| Diluted EPS | -2.5 | -4.6 | -1.9 | -3.9 | -4.4 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 27.93M | 30.08M | 31.49M | 31.97M | 29.19M |
| Total liabilities | 6.41M | 7.04M | 7.29M | 6.28M | 6.48M |
| Total equity | 21.52M | 23.04M | 24.2M | 25.68M | 22.7M |
| Cash & equivalents | 6.91M | 9.12M | 9.31M | 10.31M | 8.12M |
| Current assets | 24.78M | 26.85M | 27.97M | 27.85M | 24.48M |
| Current liabilities | 5.88M | 6.44M | 6.65M | 5.57M | 5.76M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -2.07M | -1.62M | -727.8K | -1.27M | -1.7M |
| Investing cash flow | -104.52K | -50.21K | -118.3K | -491.78K | -212.02K |
| Financing cash flow | — | 724.5K | 75.54K | 3.61M | 355.3K |
| Change in cash | -2.18M | -941.72K | -770.56K | 1.85M | -1.55M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | PRE 14C — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 424B4 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | EFFECT — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 10-Q — Sunshine Biopharma Inc. | View Filing | |
| edgar index | S-1 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | DRS — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 4 — Sunshine Biopharma Inc. | View Filing | |
| form 4 | Form 4 — NATAN DAVID | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K — Sunshine Biopharma Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14C — Sunshine Biopharma Inc. | View Filing | |
| edgar index | PRE 14C — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Sunshine Biopharma Inc. | View Filing | |
| edgar index | DEF 14A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | DEFA14A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | RW — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 424B3 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 10-Q — Sunshine Biopharma Inc. | View Filing | |
| edgar index | EFFECT — Sunshine Biopharma Inc. | View Filing | |
| edgar index | UPLOAD — Sunshine Biopharma Inc. | View Filing | |
| edgar index | CORRESP — Sunshine Biopharma Inc. | View Filing | |
| edgar index | S-1 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | POS AM — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 424B5 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 10-K — Sunshine Biopharma Inc. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | NT 10-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 3 — Sunshine Biopharma Inc. | View Filing | |
| form 3 | Form 3 — Roy Michel | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | EFFECT — Sunshine Biopharma Inc. | View Filing | |
| edgar index | UPLOAD — Sunshine Biopharma Inc. | View Filing | |
| edgar index | CORRESP — Sunshine Biopharma Inc. | View Filing | |
| edgar index | S-3 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | SC 13G/A — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 424B4 — Sunshine Biopharma Inc. | View Filing | |
| edgar index | EFFECT — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 8-K — Sunshine Biopharma Inc. | View Filing | |
| edgar index | POS AM — Sunshine Biopharma Inc. | View Filing | |
| edgar index | 10-Q — Sunshine Biopharma Inc. | View Filing |